Dyne Therapeutics, Inc. (NASDAQ:DYN) Receives $49.91 Consensus PT from Brokerages

Dyne Therapeutics, Inc. (NASDAQ:DYN) has been given a consensus recommendation of “Buy” by the thirteen brokerages that are currently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a hold rating, ten have given a buy rating and two have given a strong buy rating to the company. The average twelve-month target price among analysts that have covered the stock in the last year is $49.91.

Several equities research analysts have recently weighed in on the company. HC Wainwright reissued a “buy” rating and set a $55.00 price objective on shares of Dyne Therapeutics in a research note on Friday, January 10th. Baird R W raised Dyne Therapeutics to a “strong-buy” rating in a research note on Thursday, December 12th. Robert W. Baird initiated coverage on Dyne Therapeutics in a research note on Friday, December 13th. They set an “outperform” rating and a $46.00 price objective for the company. Chardan Capital reaffirmed a “buy” rating and issued a $50.00 target price on shares of Dyne Therapeutics in a research report on Friday, January 10th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and issued a $45.00 target price on shares of Dyne Therapeutics in a research report on Tuesday, January 14th.

Insider Buying and Selling

In other Dyne Therapeutics news, insider Oxana Beskrovnaya sold 2,334 shares of the firm’s stock in a transaction dated Wednesday, December 11th. The stock was sold at an average price of $28.12, for a total transaction of $65,632.08. Following the transaction, the insider now directly owns 201,685 shares in the company, valued at $5,671,382.20. This trade represents a 1.14 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Richard William Scalzo sold 1,455 shares of the firm’s stock in a transaction dated Wednesday, December 11th. The shares were sold at an average price of $28.12, for a total value of $40,914.60. Following the transaction, the senior vice president now owns 127,078 shares in the company, valued at approximately $3,573,433.36. This trade represents a 1.13 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 20.77% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Dyne Therapeutics

Institutional investors have recently bought and sold shares of the stock. Quantbot Technologies LP bought a new position in Dyne Therapeutics during the third quarter valued at about $34,000. Point72 DIFC Ltd bought a new position in Dyne Therapeutics during the third quarter valued at about $36,000. US Bancorp DE raised its holdings in Dyne Therapeutics by 776.9% during the third quarter. US Bancorp DE now owns 1,368 shares of the company’s stock valued at $49,000 after buying an additional 1,212 shares in the last quarter. GF Fund Management CO. LTD. bought a new position in Dyne Therapeutics during the fourth quarter valued at about $50,000. Finally, Values First Advisors Inc. bought a new position in Dyne Therapeutics during the third quarter valued at about $62,000. 96.68% of the stock is currently owned by institutional investors.

Dyne Therapeutics Stock Up 0.1 %

DYN opened at $14.01 on Tuesday. The firm has a market cap of $1.43 billion, a PE ratio of -3.94 and a beta of 1.11. The business has a fifty day simple moving average of $18.13 and a 200-day simple moving average of $28.65. Dyne Therapeutics has a fifty-two week low of $13.07 and a fifty-two week high of $47.45.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.